DURECT Corp at H C Wainwright NASH Investor Conference (Virtual) Transcript
Hello, and welcome to the H.C. Wainwright fifth annual NASH investor conference. My name is Ed Arce. I'm one of the senior biotech analysts here at H.C. Wainwright. And I am now very pleased to introduce our next presenting company, DURECT. And representing the Company is Jim Brown, the President and CEO; Mike Arenberg, the Chief Financial Officer; Dr. WeiQi Lin, the Executive Vice President of R&D and Principal Scientist; and last but not least, Dr. Norman Sussman, the Chief Medical Officer. Welcome, everyone.
Hello, Ed.
Thank you, Ed. Thanks for having us here today.
Questions & Answers
Absolutely. Glad you could join us. So let's jump right in. Of course, those that have been following your story more recently would know that DUR-928 is your lead compound.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |